CAS: 26295-56-7 - (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-alpha-L-lyxo-hexopyranoside
Fórmula:C29H28F3NO12
InChI:InChI=1S/C29H28F3NO12/c1-10-22(36)13(33-27(41)29(30,31)32)6-17(44-10)45-15-8-28(42,16(35)9-34)7-12-19(15)26(40)21-20(24(12)38)23(37)11-4-3-5-14(43-2)18(11)25(21)39/h3-5,10,13,15,17,22,34,36,38,40,42H,6-9H2,1-2H3,(H,33,41)/t10-,13-,15-,17-,22+,28-/m0/s1
Chave InChI:InChIKey=RQIOYWADAKTIJC-XUKKXQNXSA-N
SMILES:O=C1C=2C=CC=C(OC)C2C(=O)C=3C(O)=C4C(=C(O)C13)CC(O)(C(=O)CO)CC4OC5OC(C)C(O)C(NC(=O)C(F)(F)F)C5
| Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
|---|---|---|---|---|
 | N-Trifluoroacetyl Doxorubicin REF: 4Z-D-3422CAS: 26295-56-7 | - - - | A consultar | Ter 03 Dez 24 |
 | N-Trifluoroacetyladriamycin REF: TM-T25892CAS: 26295-56-7 | - - - | 494,00 € | Ter 03 Dez 24 |
 | N-Trifluoroacetyldoxorubicin REF: 3D-FT28452CAS: 26295-56-7 | Min. 95% | A consultar | Seg 13 Jan 25 |
Ref: 4Z-D-3422
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Entrega estimada em Estados Unidos, Terça-feira 3 de Dezembro de 2024
N-Trifluoroacetyladriamycin
CAS:26295-56-7
N-Trifluoroacetyladriamycin, Valrubicin's metabolite, treats bladder cancer; it's an analog of doxorubicin, infused into the bladder.
Fórmula:
C29H28F3NO12
Cor e Forma:
Solid
Peso molecular:
639.533
Ref: TM-T25892
| 5mg | 494,00 € |
Entrega estimada em Estados Unidos, Terça-feira 3 de Dezembro de 2024
N-Trifluoroacetyldoxorubicin
CAS:26295-56-7
N-Trifluoroacetyldoxorubicin is an analog of daunorubicin. It has been shown to damage the cell membrane, …
Fórmula:
C29H28F3NO12
Pureza:
Min. 95%
Peso molecular:
639.53 g/mol
Ref: 3D-FT28452
| 25mg | A consultar |
Entrega estimada em Estados Unidos, Segunda-feira 13 de Janeiro de 2025
